Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-MyersSquibb (BMY – Research Report). The associated price target remains the same with $37.00. Terence Flynn ...
BristolMyersSquibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ...
Some results have been hidden because they may be inaccessible to you